Review
Nutrition & Dietetics
Yan Jiang, Karolin Jarr, Cosima Layton, Christopher D. Gardner, Judith E. Ashouri, Maria T. Abreu, Sidhartha R. Sinha
Summary: Despite being an important issue for patients, the impact of diet on adult inflammatory bowel disease (IBD) is not well explored, with limited guidance. Current evidence on various diets used in the treatment of IBD is summarized, with potential applications of dietary data from related immune-mediated inflammatory diseases (IMIDs) to inform providers. Multiple diets, including Mediterranean, vegetarian/vegan, and reduced-calorie/fasting diets, have shown positive results in other inflammatory diseases, suggesting potential applicability to IBD, but further well-designed clinical trials are needed for guidance.
Review
Biochemistry & Molecular Biology
Laila Aldars-Garcia, Alicia C. Marin, Maria Chaparro, Javier P. Gisbert
Summary: The gut microbiota plays a crucial role in human health, contributing to the development of the immune system, digestion, metabolism, and barrier against pathogens. Inflammatory bowel disease (IBD) is characterized by an exaggerated immune reaction against intestinal microbiota, with changes in abundance of specific microorganisms associated with the disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Amy Yu, Sonia Friedman, Ashwin N. Ananthakrishnan
Summary: This study analyzed patients with pregnancy-onset IBD, and found that they were more likely to develop ulcerative colitis and had a higher risk of disease-related hospitalizations.
INFLAMMATORY BOWEL DISEASES
(2021)
Review
Medicine, General & Internal
C. R. H. Hedin, E. Sonkoly, M. Eberhardson, M. Stahle
Summary: Psoriasis and inflammatory bowel disease (IBD) are immune-mediated diseases with higher prevalence in northern Europe. Changes in gut microbiota play a key role in IBD pathogenesis, while genetic susceptibility has a greater impact on psoriasis.
JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Immunology
Masaya Yokoyama, Motoko Y. Kimura, Toshihiro Ito, Koji Hayashizaki, Yukihiro Endo, Yangsong Wang, Ryoji Yagi, Tomoo Nakagawa, Naoya Kato, Hisahiro Matsubara, Toshinori Nakayama
Summary: This study found that Myl9/12 were highly expressed in patients with inflammatory bowel disease and mice with DSS-induced colitis. Administration of anti-Myl9/12 Ab alleviated inflammation and prolonged survival, indicating Myl9/12 may be a new therapeutic target for patients with IBD.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Endocrinology & Metabolism
Wei Xian, Dide Wu, Boyuan Liu, Shubin Hong, Zijun Huo, Haipeng Xiao, Yanbing Li
Summary: Our study used bidirectional 2-sample Mendelian randomization (MR) to infer a potential causal relationship between Graves disease (GD) and inflammatory bowel disease (IBD). The results suggest that genetically predicted IBD may increase the risk of GD, while Crohn disease (CD) may increase the risk of GD and ulcerative colitis (UC) may protect against GD. However, genetically predicted GD may slightly increase the risk of CD, but there is no evidence that GD increases the risk of UC or IBD.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Gastroenterology & Hepatology
Filippos Koutroumpakis, Anna Evans Phillips, Dhiraj Yadav, Jorge D. Machicado, Maaz Ahsan, Claudia Ramos Rivers, Xiaoqing Tan, Marc Schwartz, Siobhan Proksell, Elyse Johnston, Jeffrey Dueker, Jana G. Hashash, Arthur Barrie, Janet Harrison, Michael A. Dunn, Liza Konnikova, Douglas J. Hartman, Hasieb Din, Dmitriy Babichenko, Gong Tang, David G. Binion
Summary: The study identified that IgG4 subclass deficiency is common in patients with IBD and associated with markers of disease severity. Treatment with intravenous Ig replacement therapy was beneficial in patients with IgG4-deficient severe IBD. Further research is needed to understand the mechanistic role of IgG4 deficiency in this subset of severe IBD patients.
INFLAMMATORY BOWEL DISEASES
(2021)
Review
Biochemistry & Molecular Biology
Michelle Temby, Theresa L. Boye, Jacqueline Hoang, Ole H. Nielsen, John Gubatan
Summary: This article reviews the role of kinase signaling pathways in colitis-associated colon cancer, including MAPK, CDK, autophagy-activated kinases, JAK-STAT, and other kinases. It also discusses the involvement of JAK-STAT signaling in the pathogenesis of inflammatory bowel disease (IBD) and the potential use of JAK inhibitors for treating IBD.
Article
Cell Biology
Jacob R. Sweeney, Carl Crawford, Rhonda K. Yantiss
Summary: Patients with inflammatory bowel disease (IBD) are at increased risk for Clostridioides difficile infection, although clinically important infections can be difficult to recognise. This study found that patients with C. difficile infection have symptoms and endoscopic findings that are indistinguishable from active IBD.
Article
Medicine, General & Internal
Hsu-Heng Yen, Tsui-Chun Hsu, Mei-Wen Chen, Pei-Yuan Su, Yang-Yuan Chen
Summary: In this study, the clinical features of IBD patients in Taiwan were reviewed, with UC being the predominant type and CD patients requiring more frequent biologic therapy. Subsequent research indicated a trend of decreased bowel resection for IBD patients since 2015.
Article
Immunology
Wasuwit Wanchaitanawong, Nithi Thinrungroj, Siriporn C. Chattipakorn, Nipon Chattipakorn, Krekwit Shinlapawittayatorn
Summary: Inflammatory bowel disease (IBD) is a group of intestinal disorders with increasing global incidence. Despite existing treatments not being effective for all patients, metformin has shown significant benefits for IBD and could be a promising therapeutic option.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Ugo Grossi, Gaetano Gallo, Gian Luca Di Tanna, Umberto Bracale, Mattia Ballo, Elisa Galasso, Andrea Kazemi Nava, Martino Zucchella, Francesco Cinetto, Marcello Rattazzi, Carla Felice, Giacomo Zanus
Summary: The safety and effectiveness of surgical treatment for hemorrhoidal disease in patients with inflammatory bowel disease (IBD) is currently poorly supported by evidence. However, cautious surgical management of non-responsive CD patients with inactive disease is still recommended, though further studies are needed to assess the potential benefits of non-excisional techniques in this population.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Elisabetta Antonelli, Gabrio Bassotti, Marta Tramontana, Katharina Hansel, Luca Stingeni, Sandro Ardizzone, Giovanni Genovese, Angelo Valerio Marzano, Giovanni Maconi
Summary: This review summarizes the dermatologic manifestations occurring in patients with inflammatory bowel diseases, including specific manifestations, cutaneous disorders associated with IBDs, reactive mucocutaneous manifestations of IBDs, mucocutaneous conditions secondary to treatment, and manifestations due to nutritional malabsorption. An accurate dermatological examination is crucial in all IBD patients, especially in candidates to biologic therapies where drug-induced cutaneous reactions may be clinically relevant.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Zhaobei Cai, Shu Wang, Jiannan Li
Summary: Inflammatory bowel disease (IBD) is a global disease that has attracted significant research interest. Constant research has led to a better understanding of the disease and promoted the development of conventional and novel treatments. From small molecules to cell therapy, diverse therapeutic options are emerging, offering new hope for treating IBD.
FRONTIERS IN MEDICINE
(2021)
Article
Microbiology
Ayelen D. Rosso, Pablo Aguilera, Sofia Quesada, Florencia Mascardi, Sebastian N. Mascuka, Maria C. Cimolai, Jimena Cerezo, Renata Spiazzi, Carolina Conlon, Claudia Milano, Gregorio M. Iraola, Alberto Penas-Steinhardt, Fiorella S. Belforte
Summary: Inflammatory bowel disease (IBD) presents a notable diagnostic challenge due to its clinical heterogeneity and treatment responses, especially in underdeveloped countries. This study characterized epigenetic biomarkers and gut microbial profiles in UC and CD patients in the Buenos Aires Metropolitan area for the first time, revealing differences between non-IBD controls and IBD patients.